Memory Pharmaceuticals Corp. Details:

Memory Pharmaceuticals Corp., a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of central nervous system disorders in the United States. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as certain psychiatric disorders, including schizophrenia, bipolar disorder, and depression. The company’s products for the treatment of Alzheimer’s disease comprise MEM 1414, a Phase I clinical stage product; MEM 1917, a preclinical completed product; and MEM 63908, a preclinical stage product. It is also developing MEM 3454, a Phase IIa product for the treatment of schizophrenia and/or Alzheimer’s ...